New data tells us that the 5 year survival rate for patients with lung cancer has reached an all time high of 22%. Though this is progress, we still have a long way to go. Share if you believe this number should be much higher. Visit buff.ly/3bCcEAD to read more. #LCAM

Allen et al - pembro followed by AVD in 30 patients with newly diag cHL stage II-IV. Those 'survival straight lines' just aren't budging! Looking forward to seeing the follow on randomised study which is coming. ash.confex.com/ash/2021/webpr… #ASH21 #lymsm

The #DAWNA1 phase 3 study of fulvestrant +/- dalpiciclib is out on Nature Medicine Consistently w/ other CDK4/6 inhibitors, dalpiciclib doubled PFS in ET-pretreated MBC Toxicities: mostly neutropenia, AST/ALT elevation & QT prolongation (6.7%) nature.com/articles/s4159…

Dr. Vincent Rajkumar giving a special lecture on Patient Access to #immunooncology Therapies & Country Inequalities, moderated by Dr. iman aboudalle #cmeoffice #meded #healthcare #oncology #cancer #immunooncology #AUBMC #AUB #KHCC #MIOF3

A timely lecture on inequity in cancer care due to price and access. Thank you Vincent Rajkumar for a very interesting talk American University of Beirut Medical Center ‼️Cancer drugs shortage in Lebanon 🇱🇧 will affect survival outcomes of our patients Firass Abiad Arafat Tfayli #equity #financialtoxicity

Many factors are always in inter-play.. Where the balance is flipped makes all the difference!

Défi Respire 2021 - merci à tous les participants et les supporters de la cause contre le cancer du poumon au ⁦CHUM⁩ ⁦Centre de recherche du CHUM⁩ ⁦InstitutCancerMtl⁩ interland3.donorperfect.net/weblink/weblin…

Bel effet avec Lorlatinib inhibant une protéine de fusion CLIP1-LTK. 🎯

Therapeutic Modalities in Small Cell Lung Cancer: a paradigm shift after decades of quiescence tandfonline.com/doi/full/10.10…

We keep hearing falsely reassuring stats about how many are vaccinated. (Eg 90% of over 65 “fully” vaxxed). But full protection = 3 shots, not 2 (and especially not 1 of J&J), and the entire herd matters- not just some adults. 56% of our Nation is at ⬆️ risk for BA.2.🤯

⚠️Holy moly—Gosh, 6-9% of all people across England Scotland Wales N Ireland tested newly positive for #COVID19 in just 1 week!!! Wowzers. 97-99% of people in 🇬🇧 already had antibodies. #BA2 reinfection is real. Hospitalizations surging. Don’t play games. ons.gov.uk/peoplepopulati…

That didn't take long! The #Omicron #BA2Variant is now 91% of all new #COVID19 cases in the world. gisaid.org/hcov-19-analys…

#Theranostics target unique properties of #cancer cells using different radionuclides for diagnosis & treatment nature.com/articles/s4159…

cancercontrol.info/cancer-control…

Always a great pleasure and honor to work with an amazing mentor Normand Blais, MD

Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia | NEJM nejm.org/doi/full/10.10…

Ultra-Low-Dose nivolumab (20 mg, 6% of the FDA-approved flat dose) does the job in Head and Neck Cancer. 1-year OS improved, from 16.3% to 43.4%, HR 0.545; P = .0036. Fantastic trial! De-escalation IO studies are highly needed. ascopubs.org/doi/full/10.12…

Congratulations to the medical community, our thalassemia patients , and my colleagues Khaled Musallam MD PhD for this first of its kind milestone: EU approval of Luspatercept for the management of anemia in NTD thalassemia based on data from the BEYOND trial. pubmed.ncbi.nlm.nih.gov/36007538/

#ASCO24 ASCO the eloquent Eric J. Small, MD, FASCO getting to the heart of oncology

LAURA Ph 3: Osimertinib vs Placebo #ASCO24 ASCO ➡️ mPFS: 39.1 vs 5.6 mo (HR 0.16) ‼️ ➡️ 24-mo PFS: 65% vs 13% 📈 ➡️ 81% received osi at progression 💊, Good! ➡️AE discontinuation**: 13% vs 5% ⚠️ Can't wait for Suresh S. Ramalingam, MD, FASCO's presentation today! 🎤 #ASCO24 OncoAlert Data